MétaCan
Menu
Back to cohort
Record W4399122510 · doi:10.1016/j.ejcskn.2024.100248

Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy

2024· article· en· W4399122510 on OpenAlexaboutno aff
Amanda E. Yung, Yeon Joo Jeong, Alexander H. R. Varey, Serigne Lo, Ruta Gupta, Raymond Wu, Maureen Dunn, Jenny Lee, Tsu‐Hui Low, Kerwin F. Shannon, Jonathan R. Clark, Sydney Ch’ng

Bibliographic record

VenueEJC Skin Cancer · 2024
Typearticle
Languageen
FieldMedicine
TopicNonmelanoma Skin Cancer Studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineHead and neckImmunotherapyOncologyHead and neck squamous-cell carcinomaBasal cellImmune checkpointComplete responseInternal medicineRadiation therapyHead and neck cancerChemotherapyCancerSurgery

Abstract

fetched live from OpenAlex

Background: Based on encouraging clinical outcomes in unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), the role of immune checkpoint inhibitor (ICI) immunotherapy in the (neo)adjuvant setting for earlier-stage [AJCC stage II-IV (M0)] disease is being investigated. Although pN1 disease is not included in current adjuvant trials, including C-POST (NCT03969004) and Keynote 630 (NCT03833167) where postoperative adjuvant radiotherapy remains a prerequisite, pathological staging is unavailable for neoadjuvant clinical trials and therefore, patients with isolated cN1 disease will still be included. Our anecdotal experience suggests significant differences in prognosis between the T3N0 and isolated N1 subgroups of stage III disease, with the latter having a significantly favourable outcome. Better risk-stratification of T3N0 versus isolated N1 disease is warranted to enable improved communication of the longer-term risks and benefits of neoadjuvant ICI, and critical appraisal of clinical trial data. The objective of this study is to undertake a systematic review and meta-analysis of survival outcomes in pT3N0 versus pN1 head and neck cSCC (HNcSCC). Methods: Five databases were searched for studies reporting survival outcomes (disease free survival; DFS or disease specific survival; DSS) in either pT3N0 or isolated pN1 HNcSCC between 2010 and January 2024. Two reviewers independently extracted data. Risk of bias was estimated with the Newcastle-Ottawa Scale. Kaplan-Meier curves were extracted, digitised and aggregated as per established procedure. The Kaplan-Meier method, log-rank test and univariate Cox analysis were used to describe and compare survival outcomes for aggregated pT3N0 and pN1 cohorts. Results: The aggregated groups contained 405 pT3N0 and 161 isolated pN1 patients. DFS could not be assessed due to lack of data. DSS was significantly worse for pT3N0 disease compared to pN1 disease (HR 1.800, 95% CI 1.168-2.774, log rank p-value = 0.007) with 5-year DSS of 69.3% [standard error (SE) 3.5%] for pT3N0 disease versus 81.6% (SE 3.0%) for pN1 disease (Figure 1). Figure 1 - Kaplan-Meier curve for disease specific survival in aggregated groups of patients with N1 versus T3N0 cutaneous squamous cell carcinoma of the head and neck Conclusions: The risk-benefit implications from ICI immunotherapy differ for T3N0 versus isolated N1 patients. Appreciation of the significant survival outcome difference between these two stage III subgroups is critical when designing neoadjuvant ICI clinical trials and interpreting trial data.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.054
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.327
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueEJC Skin CancerSame topicNonmelanoma Skin Cancer StudiesFrench-language works237,207